228 related articles for article (PubMed ID: 23647895)
1. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.
Shalia KK; Shah VK; Pawar P; Divekar SS; Payannavar S
Indian Heart J; 2013; 65(2):158-67. PubMed ID: 23647895
[TBL] [Abstract][Full Text] [Related]
2. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
4. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
5. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
[TBL] [Abstract][Full Text] [Related]
8. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
9. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
11. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
[TBL] [Abstract][Full Text] [Related]
13. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.
Santos PC; Soares RA; Santos DB; Nascimento RM; Coelho GL; Nicolau JC; Mill JG; Krieger JE; Pereira AC
BMC Med Genet; 2011 Jan; 12():13. PubMed ID: 21247447
[TBL] [Abstract][Full Text] [Related]
15. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T
Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897
[TBL] [Abstract][Full Text] [Related]
18. Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.
Jeong HE; Lee SJ; Cha EY; Kim EY; Kim HS; Song YH; Shin JG
Int J Mol Sci; 2014 May; 15(5):7699-710. PubMed ID: 24857912
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E
Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
